Close Menu

More articles about Informatics

The solutions being developed will leverage AI from labs globally and will accelerate the number of new test algorithms available to the lab diagnostics market.

At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.

The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.

Run by the daughter of a renowned genetic oncologist, CancerIQ is expanding and raising money as it rolls out its testing management and clinical decision support technology.

The New York Department of Health-certified tests are based on proprietary algorithms licensed from Columbia University, which offers them in the US.

Cellworks' technology predicted drug resistance in newly diagnosed patients with myelodysplastic syndromes.

The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.

At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.

The firm anticipates submitting its Acuitas AMR Gene Panel u5.47 for urinary tract infections and antibiotic resistance to US regulators by early next year.

KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.

When it comes to interfaces, storage, outcomes reporting, and HIPAA compliance, molecular lab personnel might need to demand more from their LIS vendors, researchers said.

OpGen will provide genetic panels and analysis software to the DOH's Wadsworth Center while Merck's Ilúm will provide health data aggregation and insights. 

The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.

The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.

The system relies on the use of scannable safety code cards containing patient data, along with a web portal and automated analysis tools that deliver customized diagnostic reports.

The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.

NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.

As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.

Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.

Inspirata plans to leverage Caradigm's software to accelerate the development of Inspirata's cancer big data platform called Cancer Information Data Trust.

Pages